A multicenter randomized, double-blinded placebo-controlled phase 2 trial to evaluate safety and efficacy of ilofotase alfa in patients at risk for kidney injury following open heart surgery.

Mourisse L, Ostermann M, Thiessen S, Dumoulin A, Vlaar APJ, Hoste E, Mosbahi S, Schneider A, Zarbock A, Boehm J, Rosenberger P, Thielmann M, Dubois E, Powell-Tuck J, Baig K, Renette W, Meex I, Klop-Rhiel M, Opschoor K, Vandenberghe W, Siepe M, Strauss C, Wirth F, Winkel M, Hof L, Kraan M, Bernholz J, Pickkers P, study team

Open source

DOI: 10.1007/s00134-026-08596-y
Published: 2026 Sep 21
Container: Intensive care medicine
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s00134-026-08596-y,
  title = {A multicenter randomized, double-blinded placebo-controlled phase 2 trial to evaluate safety and efficacy of ilofotase alfa in patients at risk for kidney injury following open heart surgery.},
  author = {Mourisse L and Ostermann M and Thiessen S and Dumoulin A and Vlaar APJ and Hoste E and Mosbahi S and Schneider A and Zarbock A and Boehm J and Rosenberger P and Thielmann M and Dubois E and Powell-Tuck J and Baig K and Renette W and Meex I and Klop-Rhiel M and Opschoor K and Vandenberghe W and Siepe M and Strauss C and Wirth F and Winkel M and Hof L and Kraan M and Bernholz J and Pickkers P and study team},
  year = {2026},
  journal = {Intensive care medicine},
  doi = {10.1007/s00134-026-08596-y},
  url = {https://doi.org/10.1007/s00134-026-08596-y}
}

RIS

TY  - JOUR
TI  - A multicenter randomized, double-blinded placebo-controlled phase 2 trial to evaluate safety and efficacy of ilofotase alfa in patients at risk for kidney injury following open heart surgery.
AU  - Mourisse L
AU  - Ostermann M
AU  - Thiessen S
AU  - Dumoulin A
AU  - Vlaar APJ
AU  - Hoste E
AU  - Mosbahi S
AU  - Schneider A
AU  - Zarbock A
AU  - Boehm J
AU  - Rosenberger P
AU  - Thielmann M
AU  - Dubois E
AU  - Powell-Tuck J
AU  - Baig K
AU  - Renette W
AU  - Meex I
AU  - Klop-Rhiel M
AU  - Opschoor K
AU  - Vandenberghe W
AU  - Siepe M
AU  - Strauss C
AU  - Wirth F
AU  - Winkel M
AU  - Hof L
AU  - Kraan M
AU  - Bernholz J
AU  - Pickkers P
AU  - study team
PY  - 2026
JO  - Intensive care medicine
DO  - 10.1007/s00134-026-08596-y
UR  - https://doi.org/10.1007/s00134-026-08596-y
ER  -

APA

L, M., M, O., S, T., A, D., APJ, V., E, H., S, M., A, S., A, Z., J, B., P, R., M, T., E, D., J, P., K, B., W, R., I, M., M, K., K, O., W, V., M, S., C, S., F, W., M, W., L, H., M, K., J, B., P, P., & team, S. (2026). A multicenter randomized, double-blinded placebo-controlled phase 2 trial to evaluate safety and efficacy of ilofotase alfa in patients at risk for kidney injury following open heart surgery.. Intensive care medicine. https://doi.org/10.1007/s00134-026-08596-y

Source records

pubmed · retrieved 2026-09-25T04:37:49.412Z